Lipid Phase only of Parenteral Nutrition – potential contamination with Bacillus cereus
(ITH Pharma Ltd) Small number of reported cases of bacillus cereus septicaemia affecting neonates - class 1 action now. (EL (14)A/05)
Latest UK recalls page 447
Every new product, food, vehicle, medicine and pet recall in the UK, newest first. Checked against official sources every 15 minutes. 10,759 listed.
Fybogel Orange – risk of contamination with metal particles
(Reckitt Benckiser Healthcare (UK) Limited) Remaining stock should be quarantined and returned to original supplier for credit - class 2 action within 48 hours. (EL (14)A/04)
Viread 245 mg film-coated tablets – possible presence of silicone rubber
(Gilead Sciences Limited) Pharmacists should quarantine any remaining stocks affected batches and return them to the original wholesaler for credi - class 2 action within 48 hours. (EL (14)A/03)
COSOPT preservative-free, 20mg/ml +5mg/ml, eye drops, solution, single-dose container – difficulties with administration
(Merck Sharp and Dohme) Increase in the number of adverse events and product complaints following introduction of ‘winged’ presentation - class 2 action within 48 hours. (EL (14)A/02)
Actavis Group PTC EHF – Irbesartan 300mg Film-coated tablets, PL 30306/0108 and Irbesartan / Hydrochlorothiazide 300 / 25mg Film-coated Tablets, PL 30306/0267 (MDR 94-06/18)
Actavis Group PTC EHF is recalling the below batches from pharmacies as a precautionary measure due to possible contamination with N‑nitrosodiethylamine (NDEA).
Irbesartan / Hydrochorothiazide Teva 300/12.5mg and 300/25mg film-coated tablets – incorrect dosing instruction in patient information leaflet
(Teva UK Ltd) Leaflet incorrectly states take 1 or 2 tablets a day. (EL (14)A/01)
Irbesartan 300mg film-coated tablets – blisters is incorrectly labelled as Irbesartan 150mg
(Accord Healthcare Limited) Recipients should quarantine any remaining stock and return it to supplier for credit - class 2 action within 48 hours. (EL (13)A/32)
Methotrexate 25mg/ml injection – damaged vials
(Teva UK Limited) Damaged vials so potential for a lack of sterility assurance - class 2 action within 48 hours. (EL (13)A/31)
Tixylix® liquid medicines – small pieces of plastic being found in medicine
(Novartis Consumer Health UK Ltd) Fault with tamper seal on might result in small pieces of plastic being found in medicine. Class 2 action within 48 hours (EL (13)A/30)
Class 4 drug alert (caution in use): Matrifen 100 micrograms/hour Transdermal Patch, Teva UK Livery – Takeda UK Limited
Takeda UK Limited has informed us that there is an error in the text on the pouch for batches of Matrifen 100 micrograms/hour transdermal patches distributed since 25 May 2013 in Teva UK livery.
Jext 300 and 150 micrograms solution for injection in pre-filled pens – problem with delivery of dosage
(ALK-Abelló A/S) Potential problem with delivery of dosage following activation of auto injector. Class 2 action within 48 hours (EL (13)A/28)
Class 4 Drug Alert (Caution in Use): 8.4% w/v Sodium Bicarbonate – B. Braun Melsungen AG – PL 03551/0069
This alert has been issued as B. Braun Melsungen AG has informed us that during regular visual inspection of retained samples of Sodium Bicarbonate solutions with bromobutyl stoppers precipitation in solution was observed. The…
Imigran Injection/Subject – syringes may have needles protruding from the needle shield
(GlaxoSmithKline UK) Remaining stocks of the affected batch should be quarantined and returned to the original supplier for credit – class 2 action within 48 hours. (EL (13)A/26)
NovoMix 30 Penfill 100U/ml, 3ml and NovoMix 30 FlexPen 100U/ml, 3ml – cartridges contain too much or too little insulin in batches
(Novo Nordisk A/S) Patients who may have received the affected batches should be contacted and asked to check their supply – class 2 action within 48 hours. (EL (13)A/25)
Multiple products by Wockhardt UK Limited – 2nd site certificate withdrawn
(Morningside Healthcare Limited) Remaining stocks of the affected batches should be quarantined and returned to the original supplier for credit. – class 2 action within 48 hours. (EL (13)A/24)
Natzon 0.4mg Sublingual Tablets – wrong blister packs in cartons
(Morningside Healthcare Limited) Small number of blisters containing Buprenorphine 8mg Sublingual Tablets packed in cartons labelled Natzon 0.4mg Sublingual Tablets – class 2 action within 48 hours. (EL (13)A/23)
Bydureon 2mg powder and solvent – may contain small number of under-filled vials
(Eli Lilly Nederland B.V.) Remaining stocks of affected batch should be quarantined and returned to original supplier for credit – class 2 action within 48 hours. (EL (13)A/22)
Warfarin 3mg tablets – higher than expected levels of degradation
(Teva UK Limited) Remaining stock should be quarantined and returned to original supplier for credit – class 3 action within 5 days. (EL (13) A/21)
Erythromycin Oral Suspension – manufacturers certificate withdrawn
(Pinewood Laboratories Limited) Remaining stocks of the affected batches should be quarantined and returned to the original supplier for credit – class 2 action within 48 hours. (EL (13)A/18)
Multiple products by Wockhardt UK Limited – certificate for manufacturing site withdrawn
(Wockhardt UK Limited) Remaining stocks of affected batches should be quarantined and returned to original supplier for credit – class 2 action within 48 hours (EL (13)A/19)
Hydroxyethyl starch (HES) products – increased risk of renal dysfunction and mortality
(B Braun Melsungen AG and Fresenius Kabi Limited) Increased risk of renal dysfunction and mortality in critically ill or septic patients– class 1 action within 48 hours. (EL (13)A/18)
AmBisome 50mg Powder for Solution for Infusion – potential lack of sterility assurance
(Gilead Sciences International Limited) Remaining stocks of affected batches should be quarantined and returned to the original supplier for credit – class 1 action now. (EL (13)A/17)
Ventolin Syrup sugar-free 2mg in 5ml – risk of glass fragments in the bottles
(Glaxo Wellcome UK Ltd) Source of possible contamination is believed to be sucrose used within this formulation of Questran – potential risk of glass fragments in bottles due to defect identified in very small…
Questran 4g sachet Powder for Oral Suspension – possible contamination with Enterococcus faecium
(Bristol-Myers Squibb Pharmaceuticals Limited) Source of possible contamination is believed to be sucrose used within this formulation of Questran – class 2 action within 48 hours. (EL (13)A/15)